Pembrolizumab news (page 2)

All news on Pembrolizumab (also known as KEYTRUDA): plants, production capacities, investments and involved companies.

16 October 2025

Merck's KEYNOTE-B96 Trial Shows Improved Survival in Platinum-Resistant Ovarian Cancer

The trial showed improved overall survival with KEYTRUDA in platinum-resistant ovarian cancer, with consistent safety and no new signals. Results to be presented at a future medical meeting.
9 October 2025

Merck Showcases Oncology Advances at ESMO 2025

Merck presents positive data on KEYTRUDA and other investigational medicines for various cancers, highlighting progress in treatment and research at ESMO 2025.
19 September 2025

FDA Approves Merck's Subcutaneous KEYTRUDA QLEX for Solid Tumors

KEYTRUDA QLEX, a subcutaneous immune checkpoint inhibitor, offers comparable efficacy to IV KEYTRUDA in treating metastatic NSCLC, with administration possible in one minute by healthcare providers.

Who will be producing Pembrolizumab in the future?

Find out with chemXplore Alpha

Learn more

← Previous